... are at an increased risk of chronic kidney disease, end-stage kidney disease, and mortality. Little is known about the effect of erythropoietin (EPO), a kidney-producing hormone, in post-AKI setting. We aimed to investigate the role of EPO as a predictor of long-term outcomes in post-severe AKI survivors. Methods: We...

... on maintenance hemodialysis were studied. ESA responsiveness just before starting dialysis was estimated using an erythropoietin resistance index (ERI). The endpoint was defined as all-cause death. Results: During a mean follow-up period of 3.1 ± 1.6 years, 18 (17%) patients died. Overall, the multivariate Cox...

...Alberto Rosati; Fiammetta Ravaglia; Vincenzo Panichi Hyporesponsiveness to erythropoietin stimulating agents (ESAs) is a condition associated with increased mortality. Even after identifying the condition, the causes are difficult to treat and only partially reversible in end-stage renal disease...

... to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Erythropoietin Erythropoiesis-stimulating agent resistance Erythropoiesis-stimulating agent responsiveness Vitamin E Hemodialysis Oxidative stress is commonly...

... factors for ESA hyporesponsiveness. The erythropoietin resistance index (ERI) was calculated by dividing the weekly body-weight-adjusted epoetin dose by the hemoglobin concentration. The association between ESA hyporesponsiveness estimated by the highest tertile of ERI and mortality was investigated...

... to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Erythropoietin Haemodialysis Hemoglobin Dear Editor, I read with great interest the paper published in your journal by Handelman et al. [ 1 ]. The authors...

...Angie Nishio; Bed P. Chhatkuli; Jennie Z. Ma; Kambiz Kalantari Background: Attempts to achieve near-normal hemoglobin levels have been associated with higher mortality among chronic kidney disease patients. Evidence suggests a higher mortality rate for those with resistance to erythropoietin...

..., quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Hemodialysis Hemoglobin Variability Economic analysis Erythropoietin...

.... Anemia Peritoneal dialysis Mortality Erythropoietin Iron Anemia is a common complication of chronic kidney disease (CKD) associated with adverse cardiovascular complications and is an independent risk factor for poor outcomes in patients with CKD in all stages, particularly in patients...

..., oxidative stress, energy depletion, hyperthermia, and a myriad of small molecules. Eryptosis is inhibited by a variety of substances including nitric oxide and catecholamines. Erythropoietin counteracts eryptosis in part by inhibiting the Ca 2+ -permeable cation channels. Excessive erythropoietin...

... was to compare the effects of a vitamin E-coated polysulfone (Vit E PS) membrane and a non-vitamin E-coated polysulfone (PS) membrane on inflammatory markers and resistance to erythropoietin-stimulating agents (ESAs). Methods: After a 1-month run-in period of standard bicarbonate dialysis with a synthetic...

...Michael Brines Erythropoietin (EPO) is a well-known therapeutic protein employed widely in the treatment of anemia. Over the past decade, abundant evidence has shown that in addition to its systemic role in the regulation of plasma pO 2 by modulating erythrocyte numbers, EPO is also...

... or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Erythropoiesis stimulatory agent resistance Anemia Chronic kidney disease Erythropoietin Darbepoetin Iron deficiency Inflammation In-Depth Review Blood Purif 2010;29:1 12 DOI...

... erythropoietin (rHuEPO) administration (hemoglobin 10.3 ± 1.1 g/dl) and compared with 14 hemodialysis patients not receiving the drug (hemoglobin 9.7 ± 1.4 g/dl). The sIL-2R level was higher in severely anemic patients starting rHuEPO than in patients not receiving the drug (9,414 ± 2,822 vs. 5,001 ± 2,905 pg...

...Shigeo Tomura; Yoshihiro Nakamura; Ken Tachibana; Fusae Deguchi; Ryoichi Ando; Yoshiko Chida; Fumiaki Marumo Twenty-two patients on regular hemodialysis treatment suffering from renal anemia were treated with intravenous recombinant human erythropoietin (rhEPO) for more than 8 weeks. Before and 4...

..., instructions or products referred to in the content or advertisements. Hemodialysis Malnutrition Acidosis Underdialysis Erythropoietin Proceedings Blood Purif 1992;10:35-39 Jonas Bergstrom Department of Renal Medicine, Karolinska Institute, Huddinge University Hospital, Stockholm, Sweden Anorexia...

..., instructions or products referred to in the content or advertisements. Intradialytic parenteral nutrition Malnutrition Hemodialysis Peritoneal dialysis Erythropoietin Amino acid Growth hormone Insulin-like growth factor-1 Blood Purification 13th IS B P M eeting: Viral Hepatitis in D ia lysis...

...Eugene Goldwasser A brief history of erythropoietin is presented and recent findings on the chemistry, molecular biology, receptor studies and expression of the erythropoietin gene are discussed in summary form. 30 10 2008 © 1991 S. Karger AG, Basel 1991 Copyright / Drug Dosage...

... of recombinant human erythropoietin (rHuEPO) to different types of hemodialysis membranes in vitro. The amount of rHuEPO bound was dependent on the time of incubation, the concentration of the protein offered and the membrane material. Membranes made from the copolymer of polyacrylonitrile and methallyl...

... in significant errors in ultrafiltration volume. However, with the introduction of erythropoietin therapy and the trend toward high-efficiency dialysis, increases in hematocrit and blood flow rate have led to axial variations in TMP which, if ignored, can lead to inaccurate fluid removal. The goals of this paper...